Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: Observational monocentric study of about 100 patients

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Aitelhaj, Meryem ^a   Lkhouyaali, Siham ^a   Rais, Ghizlane ^a   Mohtaram, Amina ^a   Raissouni, Soundouss ^a   Ghissassi, Brahim ^a   Boutayeb, Saber ^a   Mrabti, Hind ^a   Bensouda, Youssef ^a   Errihani, Hassan ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CARDIOTOXICITY; ETIOLOGY; FEMALE; GENE EXPRESSION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HUMAN; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXICITY; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84883073369     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-339     Document Type: Article

References (30)

1. The global breast cancer burden: variations in epidemiology and survival. Hortobagyi GN, de la Garza SJ, Pritchard K, et al. Clin Breast Cancer 2005 6 391 401 10.3816/CBC.2005.n.043 16381622 (Pubitemid 43078894)
2. Reducing the global breast cancer burden: the importance of patterns of care research. Albain KS, de la Garza SJ, Pienkowski T, et al. Clin Breast Cancer 2005 6 412 420 10.3816/CBC.2005.n.045 16381624 (Pubitemid 43078896)
3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, Science 1987 235 177 182 10.1126/science.3798106 3798106 (Pubitemid 17231334)
4. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Slamon DJ, Godolphin W, Jones LA, et al. Science 1989 244 707 712 10.1126/science.2470152 2470152 (Pubitemid 19147683)
5. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Force T, Krause DS, Van Etten RA, Nat Rev Cancer 2007 7 332 344 10.1038/nrc2106 17457301 (Pubitemid 46652481)
6. Trastuzumab-mechanism of action and use in clinical practice. Hudis CA, N Engl J Med 2007 357 39 51 10.1056/NEJMra043186 17611206 (Pubitemid 47026733)
7. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Yavas O, Yazici M, Eren O, Oyan B, Swiss Med Wkly 2007 137 556 558 17990147 (Pubitemid 47582838)
8. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV, BMC Cancer 2007 7 153 10.1186/1471-2407-7- 153 17686164 (Pubitemid 47354734)
9. Cardiotoxicity of 5-fluorouracil in a young colorectal cancer patient-case report and review of literature. Wysocki PJ, Hutka M, Arch Med Sci 2009 5 277 280
10. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. McKeage K, Perry CM, Drugs 2002 62 209 243 10.2165/00003495-200262010-00008 11790161 (Pubitemid 34169431)
11. Trastuzumab-associated cardiac adverse effects in the Herceptin Adyuvant Trial. Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. J Clin Oncol 2007 25 3859 3865 10.1200/JCO.2006.09.1611 17646669 (Pubitemid 47477261)
12. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Telli M, et al. JCO 2007 25 23 3525 3533 10.1200/JCO.2007.11.0106 (Pubitemid 47310891)
13. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. Romond EH, Perez EA, Bryant J, N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
14. 006 oboB BCIRG 006:2nd interim analysis chase III randomised trial comparing doxorubicine and cyclophosphamid followed by docetaxel (AC/T) with doxorubicine and cyclo phosphamid followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Slamon D, Eiermann W, Robert N, Proceedings of San Antonio breast cancer symposium (SABCS) San Antonio: Breast Cancer Research and Treatment 2006
15. Herceptin Adjuvant (HERA) trial study team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. N Engl J Med 2005 353 1659 1672 10.1056/NEJMoa052306 16236737 (Pubitemid 41464705)
16. Cardiotoxicity of trastuzumab in clinical practice. McArthur HL, Chia S, N Engl J Med 2007 357 94 95 10.1056/NEJMc070065 17611218 (Pubitemid 47026767)
17. Trastuzumab-related cardiotoxicity in the herceptin dyuvant trial. Montemurro F, Redana S, Valabrega G, Martinello R, Aglietta M, Almiero R, J Clin Oncol 2008 26 2052 2053 10.1200/JCO.2007.15.5044 18421060
18. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Wadhwa D, Fallah-Rad N, Grenier D, et al. Breast Cancer Res Treat 2009 117 357 364 10.1007/s10549-008- 0260-6 19082707
19. Cardiac management adjuvant trastuzumab therapy: recommendation of the Canadian Working Group. Mackey JR, Clemons M, Cote MA, et al. Current Oncol 2008 15 24 35 10.3747/co.2008.199
20. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Jones AL, Barlow M, Barrett-Lee PJ, et al. Br J Cancer 2009 100 684 692 10.1038/sj.bjc.6604909 19259090
21. Predicting cancer therapyinduced cardiotoxicity: the role of troponins and other markers. Sparano JA, Brown DL, Wolff AC, Drug Saf 2002 25 301 311 10.2165/00002018-200225050-00001 12020170 (Pubitemid 34634269)
22. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK, Mayo Clin Proc 2008 83 197 203 18241629 (Pubitemid 351303103)
23. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-over-expressing breast cancer: NSABP B-31. Tan-Chiu E, Yothers G, Romond E, et al. J Clin Oncol 2005 23 7811 7819 10.1200/JCO.2005.02.4091 16258083 (Pubitemid 46657378)
24. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the NorthCentral Cancer Treatment Group N9831 adjuvant breast cancer trial. Perez EA, Suman VJ, Davidson NE, et al. J Clin Oncol 2008 26 1231 1238 10.1200/JCO.2007.13.5467 18250349
25. Risk of heart failure in breast cancer patients after anthracyclines and Trastuzumab treatment: a retrospective cohort study. Bowles A, J Natl Cancer Inst 2012 104 1293 1305 10.1093/jnci/djs317 22949432
26. MTHFR polymorphisms and breast cancer risk. Hosseini M, Houshmand M, Ebrahimi A, Arch Med Sci 2011 7 134 137 22291746
27. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J, Angiology 2010 61 157 165 10.1177/0003319709351258 19939821
28. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Pentassuglia L, Graf M, Lane H, et al. Exp Cell Res 2009 315 1302 1312 10.1016/j.yexcr.2009.02.001 19331811
29. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Singh KK, Shukla PC, Quan A, et al. Biochem Biophys Res Commun 2011 411 421 426 10.1016/j.bbrc.2011.06.169 21749857
30. Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment. Ewer MS, Vooletich MT, Durand JB, et al. J Clin Oncol 2005 23 7820 7826 10.1200/JCO.2005.13.300 16258084 (Pubitemid 46657379)